A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 176

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016

File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death. | LitMetric
Browse Categories

A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death.

Arghya Ray Ting Du Xueping Wan Yan Song Sindhu C Pillai Md Abu Musa Teng Fang Jared Moore Brian Blank Xiaohui Du Xi Chen Robert Warne Dena Sutimantanapi Fang Lui Tatiana Zavorotinskaya Christophe Colas Lori Friedman Melissa R Junttila Dharminder Chauhan Kenneth C Anderson

Blood Cancer J

The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Published: April 2024

CD73 is the key ectoenzyme involved in the generation of AMP-derived adenosine, which contributes to immunosuppression in the MM BM milieu. Blocking CD73 activity with a potent, selective, orally bioavailable CD73 inhibitor ORIC-533 decreases adenosine generation, overcomes immune suppression, and restores immune cell-mediated MM cell lysis. Based on these preclinical studies, a multi-center clinical trial of ORIC-533 has been initiated in patients with relapsed refractory MM (NCT05227144).

Download full-text PDF

 Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11004003PMC
http://dx.doi.org/10.1038/s41408-024-01019-5DOI Listing

Publication Analysis

Top Keywords

novel small
4
small molecule
4
molecule inhibitor
4
cd73
4
inhibitor cd73
4
cd73 triggers
4
triggers immune-mediated
4
immune-mediated multiple
4
multiple myeloma
4
myeloma cell
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!

Privacy Policy Site Map

© LitMetric 2025. All rights reserved.